+54.5%
PCG vs GSK
+48.0%
+6.4%
-39.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +2.4% | -1.9% | +4.4% | +2.9% |
| 7D | -13.9% | -1.8% | -12.0% | -13.4% |
| 30D | -16.9% | -2.2% | -14.7% | -16.4% |
| 3M | -14.7% | -1.8% | -12.9% | -14.4% |
| 6M | -23.8% | -10.6% | -13.2% | -21.8% |
| YTD | -10.5% | +4.4% | -14.9% | -11.8% |
| 1Y | -5.1% | +30.4% | -35.5% | -11.9% |
| 3Y | -11.6% | +60.1% | -71.7% | -23.8% |
| All | +54.5% | +48.0% | +6.4% | +24.9% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling